中(zhong)證網訊（記者(zhe)　宋維(wei)東）東北制藥(yao)（000597）3月(yue)24日晚(wan)公(gong)(gong)告稱，公(gong)(gong)司收(shou)到遼寧省藥(yao)監(jian)局(ju)核(he)準(zhun)簽發的藥(yao)品GMP現場(chang)檢查結果通(tong)知，公(gong)(gong)司原(yuan)料(liao)藥(yao)馬來(lai)酸氨氯地平通(tong)過現場(chang)檢查，標志著馬來(lai)酸氨氯地平新生(sheng)產(chan)(chan)線已獲得(de)合法的生(sheng)產(chan)(chan)資質(zhi)(zhi)，滿足上市(shi)銷售條(tiao)件(jian)。東北制藥(yao)表示，此次通(tong)過GMP現場(chang)檢查，有(you)利于提(ti)升公(gong)(gong)司高品質(zhi)(zhi)原(yuan)料(liao)藥(yao)的生(sheng)產(chan)(chan)能(neng)力，保(bao)障公(gong)(gong)司連續穩(wen)定地提(ti)供符合質(zhi)(zhi)量(liang)標準(zhun)的產(chan)(chan)品。公(gong)(gong)司將(jiang)繼(ji)續保(bao)持良好的生(sheng)產(chan)(chan)管理和(he)質(zhi)(zhi)量(liang)保(bao)證體系，更好地滿足市(shi)場(chang)需求。